Alzheimer's therapy development: A few points to consider

Sigurdsson, 2018, Tau immunotherapies for Alzheimer's disease and related tauopathies: progress and potential pitfalls, J Alzheimers Dis, 64, S555, 10.3233/JAD-179937 Congdon, 2018, Tau-targeting therapies for Alzheimer disease, Nat Rev Neurol, 14, 399, 10.1038/s41582-018-0013-z Han, 2017, A quantitative analysis of brain soluble tau and the tau secretion factor, J Neuropathol Exp Neurol, 76, 44 Yamada, 2011, In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice, J Neurosci, 31, 13110, 10.1523/JNEUROSCI.2569-11.2011 Chai, 2012, Constitutive secretion of tau protein by an unconventional mechanism, Neurobiol Dis, 48, 356, 10.1016/j.nbd.2012.05.021 Gu, 2013, Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology, J Biol Chem., 288, 33081, 10.1074/jbc.M113.494922 McEwan, 2017, Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation, Proc Natl Acad Sci U S A, 114, 574, 10.1073/pnas.1607215114 ClinicalTrials gov Lin, 2003, Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau, J Neurocytol, 32, 1091, 10.1023/B:NEUR.0000021904.61387.95 Congdon, 2019, Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy, EBioMedicine, 42, 157, 10.1016/j.ebiom.2019.03.033 Congdon, 2013, Antibody uptake into neurons occurs primarily via clathrin-dependent fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance, J Biol Chem, 288, 35452, 10.1074/jbc.M113.491001 Congdon, 2016, Affinity of tau antibodies for solubilized pathological tau species but not their immunogen or insoluble tau aggregates predicts in vivo and ex vivo efficacy, Mol Neurodegener, 11, 62, 10.1186/s13024-016-0126-z Wu, 2018, Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging, EBioMedicine, 35, 270, 10.1016/j.ebiom.2018.08.041 Sigurdsson, 2002, Infectivity of amyloid diseases, Trends Mol Med, 8, 411, 10.1016/S1471-4914(02)02403-6 Goedert, 2014, Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies, Curr Neurol Neurosci Rep, 14, 495, 10.1007/s11910-014-0495-z Walker, 2013, Mechanisms of protein seeding in neurodegenerative diseases, JAMA Neurol, 70, 304, 10.1001/jamaneurol.2013.1453 Sandberg, 2011, Prion propagation and toxicity in vivo occur in two distinct mechanistic phases, Nature, 470, 540, 10.1038/nature09768 Diaz-Espinoza, 2018, Treatment with a non-toxic, self-replicating anti-prion delays or prevents prion disease in vivo, Mol Psychiatry, 23, 777, 10.1038/mp.2017.84 Kaufman, 2016, Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo, Neuron, 92, 796, 10.1016/j.neuron.2016.09.055 Sharma, 2018, Tau monomer encodes strains, Elife, 7, e37813, 10.7554/eLife.37813 Alzforum Therapeutics Database, https://www.alzforum.org/therapeutics/search?fda_statuses=&target_types%5B%5D=170&therapy_types=&conditions=&keywords-entry=&keywords=#results. Accessed 05/08/19 2019. Klunk, 2005, Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain, J Neurosci, 25, 10598, 10.1523/JNEUROSCI.2990-05.2005 Leuzy, 2019, Tau PET imaging in neurodegenerative tauopathies-still a challenge, Mol Psychiatry, 10.1038/s41380-018-0342-8 Fitzpatrick, 2017, Cryo-EM structures of tau filaments from Alzheimer's disease, Nature, 547, 185, 10.1038/nature23002 Falcon, 2018, Structures of filaments from Pick's disease reveal a novel tau protein fold, Nature, 561, 137, 10.1038/s41586-018-0454-y Maji, 2009, Functional amyloids as natural storage of peptide hormones in pituitary secretory granules, Science, 325, 328, 10.1126/science.1173155 Krishnaswamy, 2014, Antibody-derived in vivo imaging of tau pathology, J Neurosci, 34, 16835, 10.1523/JNEUROSCI.2755-14.2014